Hexue Mingmu tablet is a commonly used Chinese patent medicine for the treatment of retinopathy and fundus hemorrhagic diseases. It is made of 19-flavored medicine from Chuanxiong, Angelica, Red Pae, Radix, Moganlian, Nvzhenzi, Puhuang, Danpi, Danshen, Chongweizi Composition. This article reviews the chemical composition, pharmacological effects of Hexuemingmu tablets, the pharmacological effects and clinical applications of Hexuemingmu tablets, in order to provide a theoretical basis for the subsequent in-depth development and utilization and development.

Chunlan Zhang, Caiying Ren, Kai Cui. Chemical Composition, Pharmacological Effects and Clinical Research Progress of Hexuemingmu Tablets. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 9: 5-12. https://doi.org/10.25236/IJFM.2023.050902.

[1] National Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China (a 2020 edition) [M]. Beijing: China Traditional Chinese Medicine Science and Technology Press, 2020: 1149-1150. 

[2] Tang Min, Sun Fei, Liang Shengwang, etc. Research on Puhuang fingerprint and multi-component content determination method based on UPLC [J]. Traditional Chinese Medicine, 2022, 45(08): 1884-1888. 

[3] Wang Juan, Han Xu, Li Li, etc. Study on the mechanism of Moganlian-Jingzi medicine on the "same treatment of strange diseases" diabetic nephropathy and diabetic retinopathy based on online pharmacology [J]. Journal of Tianjin University of Traditional Chinese Medicine, 2021, 40(03): 374-383. 

[4] Zhou Hengpu, Ren Minxia, Guan Jiaqi, et al. Research progress on chemical constituents and pharmacological effects of Chrysanthemum morifolium and predictive analysis on quality markers [J]. Chinese patent medicine, 2019, 50(19):4785-4795. 

[5] Dong Jiaqi, Chen Jinpeng, Gong Suxiao, et al. Research progress on chemical constituents and pharmacological effects of Crataegi Fructus and predictive analysis on Q-Marker [J]. Chinese Traditional and Herbal Drugs, 2021, 52(9):2801-2818. 

[6] Jiang Xihong, Liu Shumin. Basic research on the pharmacological effects and chemical chemicals of Sage [J]. Chinese Pharmacist, 2020, 23 (10): 2004-2010. 

[7] Feng Kelan, Li Weixia, Wang Xiaoyan, etc. Predictive analysis of the chemical composition, pharmacological action and quality marker (Q-Marker) of Salvia miltiorrhiza [J]. Chinese herbal medicine, 2022, 53(02):609-618. 

[8] Wu Lingfang, Wang Zimo, He Keqian, etc. Overview of the study on the chemical composition and pharmacological effects of red peony [J]. Chinese Journal of Experimental Reagents, 2021. 27(18): 198-206. 

[9] Li Shuhui, Jin Danhong, Li Dekun, etc. Overview of the research of wood thieves I. Chemical composition research [J]. Chinese herbal medicine, 2000, 31(7):W012-W014. 

[10] Liang Yichuan, Guo Chang, Liu Sujuan, etc. The content of 7 ingredients in Chuanxiong was determined by multiple evaluation methods. Traditional Chinese Medicine, 2018, 41 (1):140-143. 

[11] Li Weixia, Ni Wenjuan, Wang Xiaoyan, etc. Predictive analysis of Angelica chemical composition, pharmacological action and quality marker (Q-marker) [J]. Journal of Chinese Medicine, 2022, 40(06): 40-48. 

[12] Zhang Shurong, Zhao Hongsu, Tong Moru. Predictive analysis of the chemical composition, pharmacological action and quality marker (Q-Marker) of peony peel [J]. Chinese herbal medicine. 2022, 53(16):5215-5224. 

[13] Sun Jianhui, Huang Yuanyuan, Guo Lanping, etc. Research progress on the chemical composition and pharmacological effects of the genus Jueming [J]. Western Chinese Medicine, 2020, 33(09): 145-159. 

[14] Guo Qi, Li Lianda, Hao Wei, etc. Effect of effective component recombinant of peony peel on platelet aggregation and coagulation function of rabbits [J]. China Modern Applied Pharmacy, 2010, 27(11): 967-970. 

[15] Cui Guozhen, Chen Yan, Guo Lin, etc. Target study on the antiplatelet coagulation effect of Salvia miltiorrhiza [J]. Chinese New Drugs and Clinical Pharmacology, 2017, 28 (04): 450-453. 

[16] Imam H. Evaluation of the larvicidal, antiplasmodial and cytotoxicity properties of cassia arereh Del. stem bark [J]. Eur J Med Plants, 2013, 3(1):78-87. 

[17] Le Na, Zhou Xue, Fei Wenting, etc. Red peony, white peony and peony glycoside and peony lactone glycoside on hemorrheology of rats with acute blood stasis Effects of vascular endothelial function [J]. Global Chinese Medicine, 2019, 12(09):1302-1307. 

[18] Wang Sanying, Wang Guofu, Mao Genxiang, etc. Research progress of endothelin-1 and cardiovascular and cerebrovascular diseases [J]. Prevention and treatment of cardiovascular and cerebrovascular diseases, 2016, 16 (04):291-293. 

[19] Ma Jing, Chen Qian, Bian Yaqian, etc. Research on the efficacy markers of salvia miltiorrhiza to promote blood circulation and remove blood stasis based on pharmacology in the system [J]. Chinese Journal of Traditional Chinese Medicine, 2020, 45 (14): 3259-3265. 

[20] Li Wei, Cai Shaoxi, Wang Yuanliang, etc. Determination of the effect of tangenol on erythrocyte deformation by microtubule sucking technology [J]. Traditional Chinese Medicine, 2001, 24(9): 662-664. 

[21] Xie Pingyao, Cui Lili, Shan Yuan, et al. Antithrombotic effect and mechanism of Radix Paeoniae Rubra [J]. BioMed research international, 2017: 1-9. 

[22] Yang Huan, Yang Yinglin, Cheng Xiao, etc. Discussion on the effect and mechanism of saccharin extract on the inflammatory response of lipopolysaccharide-induced BV2 cells [J]. Chinese Journal of Pharmacy, 2018, 53 (04): 268-272. 

[23] Jang S I, Kim H J, Kim Y J, et al. Tanshinone IIA inhibits LPS-induced NF-kappaB activation in RAW 264. 7 cells: Possible involvement of The NIK-IKK, ERK1/2, p38 and JNK pathways [J]. Eur J Pharmacol, 2006, 542(1/2/3):1-7

[24] Comalada M, Camuesco D, Sierra S, et al. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammati On through down-regulation of the NF-kappaB pathway [J]. Eur J Immunol, 2005, 35(2):584-592. 

[25] Li Jianhua. Clinical observation of He Xue Mingmu tablets in the treatment of retinal vein occlusion [J]. International Journal of Ophthalmology, 2014, 14(10):1882-1883. 

[26] Zhuang Jingling. Clinical efficacy and safety study of and Xuemingmu tablets combined with Leizhuzumab in the treatment of retinal vein occlusion and macular edema [J]. Journal of Chinese Medicine, 2021, 39(07):172-175. 

[27] Zhao Dongxian, Hong Yan, Wang Jun. Clinical effect of combined with retinal laser photocoagulation on patients with retinal vein obstructive macular edema [J]. Chinese patent medicine, 2021, 43(06):1476-1480. 

[28] Zhang Yurong, Wang Weixing. The effect of Hexue Mingmu tablets in diabetic retinopathy [J]. Chinese Medicine Guide, 2018, 16(11):42-43. 

[29] Wang Xuemei, Cui Jingqiu, Shan Chunyan. Clinical study of the treatment of diabetic retinopathy with Xuemingmu tablets and Qianledil [J]. Modern medicine and clinic, 2022, 37(04):800-804. 

[30] Zhou Liwen. Effective use of He Xue Mingmu tablets in the treatment of diabetic retinal degeneration fundus hemorrhage [J]. Modern Pharmaceutical Applications in China, 2018, 12(07): 90-92. 

[31] Yin Li, Zhang Delong, Ren Qian, etc. The effect of laser photocoagulation therapy combined with Xuemingmu tablets in the treatment of diabetic macular edema and its effect on serum vascular endothelial growth factor [J]. Journal of Modern Integrated Traditional Chinese and Western Medicine, 2017, 26 (21): 2316-2318. 

[32] Bian Wei, Wan Junli, Tan Mingqiong, etc. Longitudinal study on the quality of life and influencing factors during the treatment of patients with wet senile macular degeneration [J]. Journal of the Third Military Medical University, 2018, 40(04):356-361. 

[33] Sadda S R, Guymer R, Monés J M, et al. Anti-Vascular Endothelial Growth Factor Use and Atrophy in Neovascular Age-Related Macular Degenerat Ion: Systematic Literature Review and Expert Opinion [J]. Ophthalmology, 2020, 127(5):648-659. 

[34] Jin Ming, Chen Youxin. Guidelines for the clinical application of Chinese patent medicine for the treatment of age-related macular degeneration (wet) (2020) [J]. Chinese Journal of Integrated Traditional Chinese and Western Medicine, 2021, 41(02): 151-156. 

[35] Xu Chao, Yang Yongsheng. Clinical effect of Xuemingmu tablets combined with Leizhuzumab in the treatment of wet age-related macular degeneration [J]. Armed Police Medicine, 2019, 30 (11):956-959. 

[36] Zhan Qian, Xue Min, Jiang Lili, etc. Effects of Hexue Mingmu Tablets on correcting vision, eye ciliary posterior artery blood flow and fundus hemorrhage in wAMD patients with macular hemorrhage [J]. Chinese Journal of Gerontology, 2022, 42(04):887-889. 

[37] Chen Yanting, Li Shanxiang, He Hong. Clinical effect of Xuemingmu tablets combined with cytophosphocholine sodium on patients with glaucoma [J]. Chinese patent medicine, 2021, 43(06): 1467-1471. 

[38] Huang Heling, Fang Yiwei, Luo Jun, etc. Study on the protective effect of postoperative optic nerve function in patients with glaucoma [J]. World Journal of Western Medicine, 2016, 11(03): 364-367+371. 

[39] Li Xundi, He Liangfei, Mao Yujia. Clinical effect of Hexuemingmu tablets in the treatment of traumatic anterior atrial hemorheding [J]. Chinese Contemporary Medicine, 2021, 28 (36): 123-125. 

[40] Zhang Haifang, Kang Jie, Ma Qingmin, etc. Clinical observation of Hexuemingmu tablets in the treatment of anterior atrial hematode [J]. International Journal of Ophthalmology, 2014, 14 (09): 1710-1712. 

[41] Xiang Yang, Zhao Xiaohui. Clinical observation of the treatment of vitreous volume blood with Xuemingmu tablets and Voltiltin tablets [J]. Shizhen National Medicine and Traditional Chinese Medicine, 2015, 26(03):666-667.